Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells

被引:53
作者
Zaffaroni, N [1 ]
Silvestrini, R [1 ]
Orlandi, L [1 ]
Bearzatto, A [1 ]
Gornati, D [1 ]
Villa, R [1 ]
机构
[1] Ist Nazl Studio & Cura Tumori, Div Oncol Sperimentale C, I-20133 Milan, Italy
关键词
taxol; cisplatin; apoptosis; cell cycle-related proteins; ovarian cancer;
D O I
10.1038/bjc.1998.230
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The effect of taxol (TX) and cisplatin (CDDP), singly or in association, was assessed on two human ovarian cancer cell lines, one sensitive (A2780) and one resistant (A2780 cp8) to CDDP. Cell lines showed a similar sensitivity to TX, whereas different cytotoxicity results were obtained in the two cell lines as a function of TX and CDDP sequence. Specifically, TX followed by CDDP induced simply additive effects in both cell lines. whereas the opposite sequence produced antagonistic effects in A2780 cells and synergistic effects in A2780 cp8 cells. TX, with or without CDDP, induced oligonucleosomal DNA fragmentation typical of the apoptotic process, but the biochemical mechanisms undergoing apoptosis were different in the two cell lines. In fact, in A2780 cells, TX (with or without CDDP) treatment markedly increased p53 as well as p21(waf1) protein expression. In A2780 cp8 cells, drug treatment enhanced p53 levels, whereas the expression of p21(waf1) was always undetectable at mRNA and protein levels. In the latter cell line, a premature activation of p34(cdc2) kinase was observed in correspondence with the drug-induced increase in the S-phase cell fraction. Such an activation was not ascribable to an increase in the overall expression of p34(cdc2) or cyclin B-1 proteins, but to a dephosphorylation of p34(cdc2) kinase. Overall, our results indicate that TX-induced apoptosis in human ovarian cancer cells may be sustained by different events at the cell cycle-control level.
引用
收藏
页码:1378 / 1385
页数:8
相关论文
共 36 条
[1]  
BEHRENS BC, 1987, CANCER RES, V47, P414
[2]  
BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623
[3]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[4]   A P53-DEPENDENT MOUSE SPINDLE CHECKPOINT [J].
CROSS, SM ;
SANCHEZ, CA ;
MORGAN, CA ;
SCHIMKE, MK ;
RAMEL, S ;
IDZERDA, RL ;
RASKIND, WH ;
REID, BJ .
SCIENCE, 1995, 267 (5202) :1353-1356
[5]  
DANESI R, 1995, MOL PHARMACOL, V47, P1106
[6]  
DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041
[7]   PHASE-II STUDY AND LONG-TERM FOLLOW-UP OF PATIENTS TREATED WITH TAXOL FOR ADVANCED OVARIAN ADENOCARCINOMA [J].
EINZIG, AI ;
WIERNIK, PH ;
SASLOFF, J ;
RUNOWICZ, CD ;
GOLDBERG, GL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) :1748-1753
[8]  
ELDEIRY WS, 1994, CANCER RES, V54, P1169
[9]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[10]  
FRITSCHE M, 1993, ONCOGENE, V8, P307